Method for sample identification in a mammal as well as a kit for performing this method

• US 20040166532A1
• Filed: 12/02/2003
• Published: 08/26/2004
• Est. Priority Date: 03/15/2001
• Status: Active Grant

• Current Assignee: Ruprecht Keller
• Original Assignee: Ruprecht Keller
• Inventors: Keller, Ruprecht
• Granted Patent: US 7,820,444 B2
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: G01N 33/483 Physical analysis of biological material
• CPC Class Codes: Y10T 436/10 Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
• CPC Class Codes: Y10T 436/104165 Lipid, cholesterol, or triglyceride standard or control
• CPC Class Codes: Y10T 436/105831 Protein or peptide standard or control [e.g., hemoglobin, etc.]

Abstract

Method as well a kit for the performance of the method for the investigation of biological samples from a mammal for at least one component, wherein the method includes the following steps: (a) Administering at least one marker substance to a mammal,; (b) Waiting for a length of time which is sufficient for the at least one marker substance to reach the location of sample removal; (c) Removing a biological sample from the mammal; (d) Investigating the biological sample for the presence and/or amount of at least one marker substance or a derivative thereof; and, if the at least one marker substance or the derivative thereof is detectable in the biological sample; (e) Investigating the biological sample for an analyte.

Claims

1. A method for the investigation of biological samples from a mammal for at least one component, comprising:

(a) orally administering a combination of at least two marker substances to a mammal;

(b) waiting for a length of time which is sufficient for the combination of the at least two marker substances to reach the location of sample removal;

(c) removing a biological sample from the mammal;

(d) investigating the biological sample for the presence and/or amount of the combination of at least two marker substances or derivatives thereof; and

,

if the combination of the at least two marker substances or the derivatives thereof is detectable in the biological sample,

(e) investigating the biological sample for an analyte;

wherein the biological sample from the mammal is urine and the removal of the urine from the mammal is accomplished by collection of urine in a collection vessel, and wherein the at least two marker substances are chosen from isoprenoids, lipids, saccharides, polyols, polyethylene glycols or derivatives thereof.

2. The method of claim 1, wherein the combination of at least 2 marker substances comprises at least 3, preferably 5 marker substances.

3. The method of claim 1, wherein arabinose, erythrulose, myo-inositol, cis-inositol, mannitol, sorbose, rhamnose, sorbitol, xylose and xylulose are chosen as saccharides.

4. The method of claim 2, wherein arabinose, erythrulose, myo-inositol, cis-inositol, mannitol, sorbose, rhamnose, sorbitol, xylose and xylulose are chosen as saccharides.

5. The method of claim 1, wherein at least two polyethylene glycols of different molecular weights are used as marker substances.

6. The method of claim 2, wherein at least two polyethylene glycols of different molecular weights are used as marker substances.

7. The method of claim 3, wherein at least two polyethylene glycols of different molecular weights are used as marker substances.

8. The method of claim 4, wherein at least two polyethylene glycols of different molecular weights are used as marker substances.

9. The method of any of the previous claims, wherein the marker substance or the multitude of marker substances is detected by means of GC, GC/MS, HPLC or HPLC/MS.

10. The method of claim 1, wherein the urine samples from patients treated with methadone are investigated for intoxicants, further comprising:

(f) administering a combination of 2ⁿ−

1 polyethylene glycols of different molecular weights orally to a patient treated with methadone, wherein n is a whole number and is greater than zero, preferably at least 2, especially preferred at least 3, very especially preferred 5;

(g) waiting for a length of time of at least 30 minutes up to at most 4 hours;

(h) removing a urine sample from the excreted urine of the patient;

(i) investigating the urine sample for the presence of the administered polyethylene glycols, and;

as the case may be;

(j) investigating the urine sample for intoxicants.

11. A kit comprising a combination of at least 2, preferably at least 3, particularly preferred 5 marker substances, wherein the marker substances are chosen from isoprenoids, lipids, saccharides, polyols, polyethylene glycols or derivatives thereof.

12. The kit of claim 11, wherein the kit further comprises a combination of 2ⁿ−

1 polyethylene glycols of different molecular weights, wherein n is a whole number and greater than zero, preferably at least 2, especially preferred at least 3, very especially preferred 5.

13. The kit of claim 11, wherein the kit further comprises means for administering the marker substance.

14. The kit of claim 12, wherein the kit further comprises means for administering the marker substance.

15. The kit of claim 14, wherein the kit further comprises means for detection of the marker substances in the sample removed from a mammal.

16. The kit of claim 15, wherein the kit further comprises reference substances for the detection of the marker substances.